Abstract
The aim of this study was to examine association between IFNL4 gene ss469415590 and treatment efficiency in group of Ukrainian PEG-interferon/ribavirin-treated chronic hepatitis C patients. Study group consisted of 92 unrelated hepatitis C virus genotype 1 mono-infected patients: case group–29 patients with late or absent virological response; control group–63 patients with sustained virological response. Study material was genomic DNA. Genotyping was performed using amplification-refractory mutation system PCR. Statistical analysis was performed using GenePop and OpenEpi statistical packages. Obtained results show that ss469415590 ΔG/ΔG genotype is associated with poor virological response (OR = 3.62; CI 95%: 1.12–11.67) in PEG-interferon/ribavirin-treated chronic hepatitis C patients from Ukraine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., and Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology, 2013, vol. 57, no. 4, pp. 1333–1342.
Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gonçales, F.L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med., 2002, vol. 347, no. 13, pp. 875–982.
Kanda, T. and Yokosuka, O., Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C, J. Nepal Med. Assoc., 2011, vol. 51, no. 1, pp. 41–48.
Simmonds, P., Genetic diversity and evolution of hepatitis C virus—15 years on, J. Gen. Virol., 2003, vol. 84, no. Pt. 11, pp. 3173–3188.
Rau, M., Baur, K., and Geier, A., Host genetic variants in the pathogenesis of hepatitis C, Viruses, 2012, vol. 4, no. 12, pp. 3281–3302.
Mukherjee, R., Burns, A., Rodden, D., Chang, F., Chaum, M., Garcia, N., Bollipalli, N., and Niemz, A., Diagnosis and management of hepatitis C virus infection, J. Lab. Autom., 2015, vol. 20, no. 5, pp. 519–538.
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., Ito, Y., Mita, E., Tanaka, E., Mochida, S., Murawaki, Y., Honda, M., Sakai, A., Hiasa, Y., Nishiguchi, S., Koike, A., Sakaida, I., Imamura, M., Ito, K., Yano, K., Masaki, N., Sugauchi, F., Izumi, N., Tokunaga, K., and Mmizokami, M., Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat. Genet., 2009, vol. 41, no. 10, pp. 1105–1109.
Matsuura, K., Watanabe, T., and Tanaka, Y., Role of IL28B for chronic hepatitic C treatment toward personalized medicine, J., Gastroenterol. Hepatol., 2014, vol. 29, pp. 241–249.
Hajarizadeh, B., Grebely, J., and Dor, G.J., Epidemiology and natural history of HCV infection, Nat. Rev. Gastroenterol. Hepatol., 2013, vol. 10, no. 9, pp. 553–562.
Prokunina-Olsson, L., Muchmore, B., Tang, W., Pfeiffer, R.M., Park, H., Dickensheets, H., Hergott, D., Porter-Gill, P., Mumy, A., Kohaar, I., Chen, S., Brand, N., Tarway, M., Liu, L., Sheikh, F., Astemborski, J., Bonkovsky, H.L., Edlin, B.R., Howell, C.D., Morgan, T.R., Thomas, D.L., Rehermann, B., Donnelly, R.P., and O’Brien, T.R., A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus, Nat. Genet., 2013, vol. 45, no. 2, pp. 164–171.
Meissner, E.G., Bon, D., Prokunina-Olsson, L., Tang, W., Masur, H., O’Brien, T.R., Herrmann, E., Kottilil, S., and Osinusi, A., IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin, J. Infect. Dis., 2014, vol. 209, no. 11, pp. 1700-1704.
O’Brien, T.R., Prokunina-Olsson, L., and Donnelly, R.P., IFN-Δ4: the paradoxical new member of the interferon lambda family, J. Interferon Cytokine Res., 2014, vol. 39, no. 8, pp. 555–564.
Real, L.M., Neukam, K., Herroro, R., Guardiola, J.M., Reiberger, T., Rivero-Juarez, A., Salazar, J., Mandorfer, M., Merino, D., Soriano, V., Rivero, A. Macías, J., Pineda, J.A., and Caruz, A., IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians, PLoS One, 2014, vol. 9, no. 5, pp. 1–6.
Aka, P.V., Kuniholm, M.H., Pfeiffer, R.M., Wang, A.S., Tang, W., Chen, S., Astemborski, J., Plankey, J.M., Villacres, M.C., Peters, M.G., Desai, S., Seaberg, E.C., Edlin, B.R., Strickler, H.D., Thomas, D.L., Prokunina-Olsson, L., Sharg, G.B., and O’Brien, T.R., Association of the IFNL4-?G allele with impaired spontaneous clearance of hepatitis C virus, J. Infect. Dis., 2014, vol. 209, no. 3, pp. 350–354.
Konishi, H., Motomura, T., Matsumoto, Y., Harimoto, N., Ikegami, T., Yoshizumi, T., Soejima, Y., Shirabe, K., Fukuhara, T., and Maehara, Y., Interferon- lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant, J. Viral Hetap., 2014, vol. 21, pp. 397–404.
Khudayberganova, D., Sugiyama, M., Masaki, N., Nishida, N., Mukaide, M., Sekler, D., Latipov, R., Nataliya, K., Dildora, S., Sharapov, S., Usmanova, G., Raxmanov, M., Musabaev, E., and Mizokami, M., IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan, PLoS One, 2014, vol. 9, no. 3, pp. 3–7.
Kucherenko, A.M., Pampukha, V.M. and Livshits, L.A., Study on the IFNL4 gene ss469415590 variant in Ukrainian population, Biopolym. Cell, 2014, vol. 30, no. 5, pp. 400–402.
Pampukha, V.M., Kravchenko, S.A., Moroz, L.V., and Livshits, L.A., IFN-Δ-3 (IL28B) genotyping by restriction fragment length polymorphism method: detection polymorphism of rs12979860, Biopolym. Cell, 2011, vol. 27, no. 3, pp. 231–234.
Rousset, F., Genopop’007: a complete re-implementation of the genopop software for Windows and Linux, Mol. Ecol. Resour., 2008, vol. 8, no. 1, pp. 103–106.
Sullivan, K.M., Dean, A., and Soe, M.M., OpenEpi: a web-based epidemiologic and statistical calculator for public health, Public Heal. Rep., 2009, vol. 124, no. 3, pp. 471–474.
Amanzada, A. Kopp Spengler, W.U., Ramadori, G., and Mihm, S., Interferon-Δ4 (IFNL4) transcript expression in human liver tissue samples, PLoS One, 2013, vol. 8, no. 12, p. e84026.
Hamming, O.J., Terczynska-Dyla, E., Vieyres, G., Dijkman, R., Jørgensen, S.E., Akhtar, H, Siupka, P., Pietschmann, T., Thiel, V., and Hartmann, R., Interferon lambda 4 signals via the IFN? receptor to regulate antiviral activity against HCV and coronaviruses, EMBO J., 2013, vol. 32, no. 23, pp. 3055–3065.
Pott, J., Mahlakõiv, T., Mordstein, M., Duerr, C.U., Michiels, T., Stodkinger, S., Staeheli, P., and Hornef, M.W., IFN-lambda determines the intestinal epithelial antiviral host defense, Proc. Natl. Acad. Sci. U. S. A., 2011, vol. 108, no. 19, pp. 7944–7949.
Muir, A.J., Shiffman, M.L., Zaman, A., Yoffe, B., de la Torre, A., Flamm, S., Gordon, C., Marotta, P., Vierling, J.M., Lopez-Talavera, J.C., Byrnes-Blake, K., Fontana, D., Freeman, J., Gray, T., Hausman, D., Hunder, N.N., and Lawitz, E., Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection, Hepatology, 2010, vol. 52, no. 3, pp. 822–832.
Muir, A.J., Arora, S., Everson, G., Flisiak, R., George, J., Ghalib, R., Gordon, S.C., Gray, T., Greenbloom, S., Hassanein, T., Hillson, J., Horga, M.A., Jacobson, I.M., Jeffers, L., Kowdley, K.V., Lawitz, E., Lueth, S., Rodriguez-Torres, M., Rustgi, V., Shemanski, L., Shiffman, M.L., Srinivasan, S., Vargas, H.E., Vierling, J.M., Xu, D., Lopez-Talavera, J.C., and Zeuzem, S., A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection, J. Hepatol., 2014, vol. 61, no. 6, pp. 12138–1246.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Ukrainian Text © A.M. Kucherenko, V.M. Pampukha, K.Yu. Romanchuk, S.Yu. Chernushyn, I.A. Bobrova, L.V. Moroz, L.A. Livshits, 2016, published in Tsitologiya i Genetika, 2016, Vol. 50, No. 5, pp. 79–84.
The article was translated by the authors.
About this article
Cite this article
Kucherenko, A.M., Pampukha, V.M., Romanchuk, K.Y. et al. IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients. Cytol. Genet. 50, 330–333 (2016). https://doi.org/10.3103/S0095452716050066
Received:
Published:
Issue Date:
DOI: https://doi.org/10.3103/S0095452716050066